Hookipa Pharma, Inc. Forecast, price target & analysts
Hookipa Pharma, Inc. Target price 2025 - Analyst rating & recommendation
Hookipa Pharma, Inc. Classifications & Recommendation:
Hookipa Pharma, Inc. Price Target
| Target Price | $29.07 |
| Price | $1.25 |
| Potential |
2,225.60%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Hookipa Pharma, Inc. 2026 .
The average Hookipa Pharma, Inc. target price is $29.07.
This is
2,225.60%
register free of charge
$52.50
4,100.00%
register free of charge
$7.07
465.60%
register free of charge
|
|
| A rating was issued by 7 analysts: 0 Analysts recommend Hookipa Pharma, Inc. to buy, 4 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hookipa Pharma, Inc. stock has an average upside potential 2026 of
2,225.60%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 43.95 | 25.50 |
| 118.33% | 41.98% | |
| EBITDA Margin | -101.91% | -341.20% |
| 75.85% | 234.80% | |
| Net Margin | -98.98% | -108.61% |
| 75.58% | 9.73% |
3 Analysts have issued a sales forecast Hookipa Pharma, Inc. 2025 . The average Hookipa Pharma, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Hookipa Pharma, Inc. EBITDA forecast 2025. The average Hookipa Pharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-44.8m | 47.26% |
|---|---|---|
| 2025 |
$-87.0m
94.25%
Unlock
|
|
EBITDA Margin
| 2024 | -101.91% | 75.85% |
|---|---|---|
| 2025 |
-341.20%
234.80%
Unlock
|
|
4 Hookipa Pharma, Inc. Analysts have issued a net profit forecast 2025. The average Hookipa Pharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.47 | -2.29 |
| 59.79% | 34.01% | |
| P/E | negative | |
| EV/Sales | negative |
4 Analysts have issued a Hookipa Pharma, Inc. forecast for earnings per share. The average Hookipa Pharma, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Hookipa Pharma, Inc....
Current Hookipa Pharma, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Nov 21 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Nov 21 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 15 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
